Clinical Trial Update: Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating KHK7580 for secondary hyperparathyroidism in patients receiving hemodialysis has completed. The sponsor is Kyowa Kirin Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• KHK7580

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Hyperparathyroidism | Phase 1, Phase 2 | Status: COMPLETED